Table 3.

Therapeutic efficacy of three artemisinin-based combination therapies at five monitoring sites, Democratic Republic of the Congo, 2017

		Kaplan-Meier				Per-protocol
		Uncorrected % (95% CI)		PCR-corrected % (95% CI)*		Uncorrected % (95% CI)		PCR-corrected % (95% CI)*
Site	Drug	28 days	42 days	28 days	42 days	28 days	42 days	28 days	42 days
Kabondo	AL	88 (82, 95)	–	98 (95, 100)	–	88 (79, 94)	–	98 (92, 100)	–
	ASAQ	100 (100–100)	–	100 (100, 100)	–	100 (96, 100)	–	100 (96, 100)	–
	DP	99 (96, 100)	91 (85, 98)	100 (100, 100)	100 (99, 100)	99 (93, 100)	91 (81, 96)	100 (95, 100)	100 (94, 100)
Kapolowe	AL	76 (68, 85)	–	94 (89, 99)	–	75 (65, 84)	–	93 (84, 97)	–
	ASAQ	100 (100, 100)	–	100 (100, 100)	–	100 (96, 100)	–	100 (96, 100)	–
	DP	89 (83, 96)	64 (56, 75)	98 (94, 100)	93 (87, 99)	89 (81, 95)	64 (53, 74)	96 (90, 99)	91 (82, 97)
Kimpese	AL	85 (78, 94)	–	96 (92, 100)	–	85 (75, 92)	–	96 (88, 99)	–
	ASAQ	93 (88, 99)	–	99 (98, 100)	–	93 (84, 97)	–	100 (95, 100)	–
	DP	99 (97, 100)	90 (84, 97)	100 (100, 100)	100 (99, 100)	99 (93, 100)	90 (81, 96)	100 (96, 100)	100 (95, 100)
Mikalayi	AL	63 (55, 74)	–	86 (79, 93)	–	63 (52, 73)	–	82 (71, 90)	–
	ASAQ	77 (69, 86)	–	96 (91, 99)	–	76 (66, 85)	–	95 (86, 99)	–
	DP	83 (76.91)	56 (47, 67)	97 (94, 100)	84 (75, 93)	83 (73, 90)	56 (45, 66)	88 (89, 94)	80 (68, 89)
Rutshuru	AL	80 (72, 89)	–	96 (92, 100)	–	80 (70, 88)	–	96 (88, 99)	–
	ASAQ	73 (64, 83)	–	91 (85, 98)	–	72 (61, 81)	–	91 (81, 97)	–
	DP	75 (67, 85)	59 (50, 70)	97 (93, 100)	95 (90, 100)	75 (65, 84)	59 (48, 69)	99 (92, 100)	93 (83, 98)

AL = artemether-lumefantrine; ASAQ = artesunate-amodiaquine; DP = dihydroartemisinin-piperaquine; PCR = polymerase chain reaction. Bold indicates point estimate of PCR-corrected efficacy < 90%.

^*Number of treatment failures calculated as the sum of posterior probabilities of recrudescence.